Aryl Compounds Enhancing PPARδ Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PPARδ ligands lack selectivity and only induce activity from 30-40% of total ligand-binding pockets, limiting their effectiveness in treating obesity, diabetes, and arteriosclerosis.
Innovation Solution
A novel compound represented by formula (I) with specific structural features, including aryl groups and metal substitutions, is developed to enhance PPARδ selectivity and activity, formulated into pharmaceutical, cosmetic, and functional food compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PPARδ ligands are used, then some PPARδ activity is achieved (30-40% of total ligand-binding pockets), but selectivity is insufficient and effectiveness is limited
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R6) at particular positions on the aromatic ring structure. These localized modifications at specific sites (ortho, meta, para positions) enhance PPARδ selectivity while maintaining overall molecular functionality, resolving the contradiction between selectivity and effectiveness.
Solution Approach 2:
The patent employs parameter changes by systematically varying substituent types (halogens, alkyl groups, alkoxy groups) and their positions on the aromatic ring. This chemical parameter optimization transforms the ligand structure to achieve both high PPARδ selectivity and therapeutic effectiveness, overcoming the limitations of existing ligands.
2Productivity
If PPARδ activity is enhanced, then effectiveness in treating metabolic diseases improves, but selectivity over other PPAR subtypes may decrease
Solution Approach 1:
The patent applies segmentation by dividing the ligand structure into distinct functional regions: the core aromatic ring system and six variable substituent positions (R1-R6). This segmentation allows independent optimization of PPARδ binding affinity and subtype selectivity, enabling enhanced effectiveness without sacrificing selectivity.
Data Source
AI summary
The present invention relates to a compound as a peroxisome proliferator activated receptor (PPAR) activator and a hydrate, a solvate, a stereoisomer and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition, a cosmetic composition, a muscle strengthening agent, a memory improving agent, a therapeutic agent for dementia and Parkinson's disease, a functional food and a feed composition containing the same.